AU707130B2 - Methods for enhancing the production of viral vaccines in cell culture by interferon suppression - Google Patents
Methods for enhancing the production of viral vaccines in cell culture by interferon suppression Download PDFInfo
- Publication number
- AU707130B2 AU707130B2 AU68608/96A AU6860896A AU707130B2 AU 707130 B2 AU707130 B2 AU 707130B2 AU 68608/96 A AU68608/96 A AU 68608/96A AU 6860896 A AU6860896 A AU 6860896A AU 707130 B2 AU707130 B2 AU 707130B2
- Authority
- AU
- Australia
- Prior art keywords
- virus
- cell culture
- deficient
- pkr
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 48
- 108010050904 Interferons Proteins 0.000 title claims abstract description 44
- 102000014150 Interferons Human genes 0.000 title claims abstract description 42
- 229940079322 interferon Drugs 0.000 title claims abstract description 41
- 229960004854 viral vaccine Drugs 0.000 title claims abstract description 21
- 230000002708 enhancing effect Effects 0.000 title abstract description 4
- 230000001629 suppression Effects 0.000 title description 6
- 230000002950 deficient Effects 0.000 claims abstract description 108
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 claims abstract description 38
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 claims abstract description 37
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 28
- 102000003960 Ligases Human genes 0.000 claims abstract description 13
- 108090000364 Ligases Proteins 0.000 claims abstract description 13
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 154
- 241000700605 Viruses Species 0.000 claims description 123
- 230000000694 effects Effects 0.000 claims description 83
- 229960005486 vaccine Drugs 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 108010037623 eIF-2 Kinase Proteins 0.000 claims description 10
- 102000010982 eIF-2 Kinase Human genes 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 238000001890 transfection Methods 0.000 claims description 10
- 230000001524 infective effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 241000712461 unidentified influenza virus Species 0.000 claims description 9
- 102000001617 Interferon Receptors Human genes 0.000 claims description 7
- 108010054267 Interferon Receptors Proteins 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 7
- 206010022000 influenza Diseases 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 claims description 5
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 230000005860 defense response to virus Effects 0.000 claims description 5
- 238000012224 gene deletion Methods 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 230000004952 protein activity Effects 0.000 claims description 5
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical group NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 210000001995 reticulocyte Anatomy 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 210000003501 vero cell Anatomy 0.000 claims description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 2
- 235000019365 chlortetracycline Nutrition 0.000 claims description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims 17
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 20
- 230000003612 virological effect Effects 0.000 abstract description 20
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 19
- 102000020233 phosphotransferase Human genes 0.000 abstract description 19
- 230000001419 dependent effect Effects 0.000 abstract description 8
- 210000004102 animal cell Anatomy 0.000 abstract description 6
- 230000001413 cellular effect Effects 0.000 abstract description 5
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 20
- 238000003556 assay Methods 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 241000710188 Encephalomyocarditis virus Species 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000035578 autophosphorylation Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 244000052613 viral pathogen Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 108091008023 transcriptional regulators Proteins 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 3
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000001840 diploid cell Anatomy 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108090000656 Annexin A6 Proteins 0.000 description 2
- 102100034278 Annexin A6 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000008014 Eukaryotic Initiation Factor-2 Human genes 0.000 description 2
- 108010089791 Eukaryotic Initiation Factor-2 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 102000048122 human MX1 Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101150091206 Nfkbia gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- -1 alum Chemical compound 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000044003 human EIF2AK2 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 208000037802 influenza A (H3N2) Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 229940126581 whole-virion vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US262195P | 1995-08-22 | 1995-08-22 | |
| US60/002621 | 1995-08-22 | ||
| PCT/US1996/013745 WO1997008292A1 (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6860896A AU6860896A (en) | 1997-03-19 |
| AU707130B2 true AU707130B2 (en) | 1999-07-01 |
Family
ID=21701659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU68608/96A Expired AU707130B2 (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
| AU68576/96A Abandoned AU6857696A (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of interferon in cell culture |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU68576/96A Abandoned AU6857696A (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of interferon in cell culture |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US5840565A (https=) |
| EP (2) | EP0846174A4 (https=) |
| JP (2) | JP3432519B2 (https=) |
| CN (1) | CN1161469C (https=) |
| AT (1) | ATE289348T1 (https=) |
| AU (2) | AU707130B2 (https=) |
| BR (1) | BR9610550A (https=) |
| CA (2) | CA2229405C (https=) |
| DE (1) | DE69634360T2 (https=) |
| WO (2) | WO1997008324A1 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855519B2 (en) * | 1995-08-22 | 2005-02-15 | The Regents Of The University Of California | Methods for enhancing the production of interferon in cell culture |
| US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| US6740519B1 (en) | 1997-11-03 | 2004-05-25 | Mount Sinai School Of Medicine | Immortalized, homozygous stat1-deficient mammalian cell lines and their uses |
| KR100637937B1 (ko) * | 1998-06-12 | 2006-10-23 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스 |
| US6762038B1 (en) | 1998-09-09 | 2004-07-13 | The Cleveland Clinic Foundation | Mutant cell lines and methods for producing enhanced levels of recombinant proteins |
| CA2376487A1 (en) * | 1999-06-15 | 2000-12-21 | Allan S. Lau | Methods for enhancing the production of cytokines in cell culture |
| EP1067179A1 (en) * | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
| AU7126000A (en) * | 1999-09-08 | 2001-04-10 | Genetrol Biotherapeutics, Inc. | High level cytokine production with enhanced cell viability |
| US20010031859A1 (en) * | 1999-09-08 | 2001-10-18 | Lau Allan S. | High level cytokine production with enhanced cell viability |
| WO2001077394A1 (en) | 2000-04-10 | 2001-10-18 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
| IL136232A0 (en) * | 2000-05-18 | 2001-05-20 | Bar Ilan University Res Author | Measurements of enzymatic activity in a single, individual cell in population |
| US6660471B2 (en) * | 2000-08-04 | 2003-12-09 | Chiron Corporation | Enhanced replication of HCV RNA |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| AU2001290855A1 (en) | 2000-09-14 | 2002-03-26 | Genetrol Biotherapeutics, Inc. | Method and cell composition for screening compounds for anti-inflammatory activity |
| US20020115212A1 (en) * | 2000-12-19 | 2002-08-22 | Browning Laura A. | Enchanced PKR expression and cytokine production |
| DE10104094C1 (de) * | 2001-01-31 | 2002-07-25 | Angelika Vallbracht-Flehmig | Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung |
| WO2003035824A1 (en) * | 2001-10-25 | 2003-05-01 | Bar-Ilan University | Interactive transparent individual cells biochip processor |
| IL154677A0 (en) | 2003-02-27 | 2003-09-17 | Univ Bar Ilan | A method and apparatus for manipulating an individual cell |
| EP1654347B1 (en) * | 2003-06-26 | 2014-06-04 | Seng Enterprises Limited | Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof |
| US8597597B2 (en) | 2003-06-26 | 2013-12-03 | Seng Enterprises Ltd. | Picoliter well holding device and method of making the same |
| US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
| US7888110B2 (en) | 2003-06-26 | 2011-02-15 | Seng Enterprises Ltd. | Pico liter well holding device and method of making the same |
| WO2005008626A1 (en) * | 2003-07-11 | 2005-01-27 | University Of North Carolina At Chapel Hill | Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop |
| US20050064524A1 (en) * | 2003-08-11 | 2005-03-24 | Mordechai Deutsch | Population of cells utilizable for substance detection and methods and devices using same |
| RU2390351C2 (ru) * | 2003-08-11 | 2010-05-27 | Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити | Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа |
| JP2007529199A (ja) * | 2003-10-23 | 2007-10-25 | イルミジェン バイオサイエンシーズ， インコーポレイテッド | ウイルス感染に対する抵抗性に関連する遺伝子である、ｏａｓ１における変異の検出 |
| US20050191649A1 (en) * | 2003-10-23 | 2005-09-01 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| BRPI0506610A (pt) * | 2004-02-03 | 2007-05-02 | Chemagis Ltd | montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico |
| NZ548495A (en) * | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| EP3332803B1 (en) | 2004-06-01 | 2021-09-08 | Icahn School of Medicine at Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
| EP1763665A1 (en) * | 2004-07-07 | 2007-03-21 | Seng Enterprises Limited | Method and device for identifying an image of a well in an image of a well-bearing component |
| US7403647B2 (en) * | 2004-09-13 | 2008-07-22 | Seng Enterprises Ltd. | Method for identifying an image of a well in an image of a well-bearing component |
| WO2006021959A2 (en) * | 2004-08-25 | 2006-03-02 | Seng Enterprises Ltd. | Method and device for isolating cells |
| US20060051369A1 (en) * | 2004-08-27 | 2006-03-09 | Taylor Deborah R | ADAR1 antiviral pathway |
| US20080107683A1 (en) * | 2004-11-30 | 2008-05-08 | David Hone | Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof |
| EP1866075B1 (en) | 2005-01-25 | 2010-09-08 | Seng Enterprises Limited | Microfluidic device for studying cells |
| WO2006088481A2 (en) | 2005-02-15 | 2006-08-24 | Mount Sinai School Of Medicine Of New York University | Genetically engineered equine influenza virus and uses thereof |
| DK1869171T4 (en) * | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| UA95446C2 (ru) * | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Мутаци в генах oas1 |
| DE102005034043B4 (de) * | 2005-07-18 | 2019-12-12 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch |
| US20070111309A1 (en) * | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
| US20070141555A1 (en) * | 2005-10-11 | 2007-06-21 | Mordechai Deutsch | Current damper for the study of cells |
| WO2007052245A1 (en) | 2005-11-03 | 2007-05-10 | Seng Enterprises Ltd. | Method and device for studying floating, living cells |
| US20070196333A1 (en) * | 2006-02-23 | 2007-08-23 | Fu-Yung Lin | Composition comprising mixtures of IFN-alpha subtypes |
| US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
| MX2009011870A (es) | 2007-05-02 | 2009-11-12 | Ambrx Inc | Polipeptidos de interferon beta modificados y usos de los mismos. |
| US9145540B1 (en) | 2007-11-15 | 2015-09-29 | Seng Enterprises Ltd. | Device for the study of living cells |
| EP2237887A2 (en) | 2007-12-26 | 2010-10-13 | Seng Enterprises Ltd. | Device for the study of living cells |
| NZ586947A (en) | 2008-02-08 | 2012-11-30 | Ambrx Inc | Modified leptin polypeptides and their uses |
| EP2133358A1 (en) * | 2008-06-10 | 2009-12-16 | Universitätsklinikum Freiburg | Rift valley fever virus-like particles and their use for immunization and as test system |
| MY172788A (en) | 2008-08-01 | 2019-12-12 | Gamma Vaccines Pty Ltd | Influenza vaccines |
| JP5686741B2 (ja) | 2008-12-16 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | インフルエンザワクチンの生成 |
| US9644187B2 (en) | 2010-04-14 | 2017-05-09 | Emd Millipore Corporation | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| US20140079732A1 (en) | 2011-01-27 | 2014-03-20 | Gamma Vaccines Pty Limited | Combination vaccines |
| WO2013182498A1 (en) * | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
| KR20150133695A (ko) * | 2013-02-05 | 2015-11-30 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 바이러스 제조를 위한 세포주 및 이의 사용 방법 |
| JP6722686B2 (ja) | 2015-02-26 | 2020-07-15 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | 二価ブタインフルエンザウイルスワクチン |
| WO2017070167A1 (en) * | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
| KR102651055B1 (ko) | 2016-03-24 | 2024-03-26 | 삼성디스플레이 주식회사 | 광학 필름 및 디스플레이 장치 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
| JPS5754586A (en) * | 1980-09-18 | 1982-04-01 | Ajinomoto Co Inc | Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it |
| US4579821A (en) * | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| JPS58209993A (ja) * | 1982-05-31 | 1983-12-07 | Mochida Pharmaceut Co Ltd | インタ−フエロンの産生方法 |
| CA1211397A (en) * | 1982-06-21 | 1986-09-16 | Michael D. Johnston | Production of antiviral agents |
| US4485038A (en) * | 1982-10-19 | 1984-11-27 | Health Research (Roswell Park Division) | Method for the production and purification of human leukocyte interferon |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4745053A (en) * | 1983-07-08 | 1988-05-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo | Process for producing human interferon and method for assaying the interferon productivity of blood |
| JPS6062997A (ja) * | 1983-09-17 | 1985-04-11 | Mochida Pharmaceut Co Ltd | インタ−フエロンの生産方法 |
| US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| EP0414475B1 (en) * | 1989-08-25 | 1997-12-10 | Chiron Corporation | Methods for culturing HCV in B- or T-lymphocyte cell lines |
| US5149531A (en) * | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
| JPH05260981A (ja) * | 1992-03-02 | 1993-10-12 | Massachusetts Inst Of Technol <Mit> | ヘムに調節される真核細胞開始因子２αキナーゼをコードするＤＮＡ |
| FR2689520B1 (fr) * | 1992-04-03 | 1996-07-19 | Bio Merieux | Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques. |
| US5840565A (en) | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
-
1996
- 1996-08-21 US US08/700,198 patent/US5840565A/en not_active Expired - Lifetime
- 1996-08-22 AU AU68608/96A patent/AU707130B2/en not_active Expired
- 1996-08-22 CN CNB961977515A patent/CN1161469C/zh not_active Expired - Fee Related
- 1996-08-22 WO PCT/US1996/013627 patent/WO1997008324A1/en not_active Ceased
- 1996-08-22 AU AU68576/96A patent/AU6857696A/en not_active Abandoned
- 1996-08-22 EP EP96929017A patent/EP0846174A4/en not_active Withdrawn
- 1996-08-22 EP EP96929066A patent/EP0846160B1/en not_active Expired - Lifetime
- 1996-08-22 WO PCT/US1996/013745 patent/WO1997008292A1/en not_active Ceased
- 1996-08-22 BR BR9610550A patent/BR9610550A/pt not_active Application Discontinuation
- 1996-08-22 AT AT96929066T patent/ATE289348T1/de active
- 1996-08-22 JP JP51045097A patent/JP3432519B2/ja not_active Expired - Fee Related
- 1996-08-22 CA CA002229405A patent/CA2229405C/en not_active Expired - Fee Related
- 1996-08-22 DE DE69634360T patent/DE69634360T2/de not_active Expired - Lifetime
- 1996-08-22 CA CA2229163A patent/CA2229163C/en not_active Expired - Lifetime
- 1996-08-22 JP JP51050897A patent/JP4267693B2/ja not_active Expired - Lifetime
-
1999
- 1999-11-19 US US09/444,224 patent/US6159712A/en not_active Expired - Fee Related
-
2000
- 2000-06-12 US US09/591,813 patent/US6489144B1/en not_active Expired - Fee Related
- 2000-12-13 US US09/737,126 patent/US6686190B2/en not_active Expired - Lifetime
- 2000-12-13 US US09/736,748 patent/US6673591B2/en not_active Expired - Fee Related
-
2003
- 2003-11-24 US US10/722,349 patent/US7132271B2/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| J.GEN VIROL.(1988) 69, 1637-45 * |
| J.VIROL.(1992) 66(10), 5805-14 * |
| VIROLOGY(1993) 193, 1037-4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0846160B1 (en) | 2005-02-16 |
| AU6860896A (en) | 1997-03-19 |
| JP4267693B2 (ja) | 2009-05-27 |
| US6489144B1 (en) | 2002-12-03 |
| JP3432519B2 (ja) | 2003-08-04 |
| AU6857696A (en) | 1997-03-19 |
| US6686190B2 (en) | 2004-02-03 |
| BR9610550A (pt) | 1999-07-06 |
| CA2229163A1 (en) | 1997-03-06 |
| CN1200148A (zh) | 1998-11-25 |
| US20040157310A1 (en) | 2004-08-12 |
| US20010001709A1 (en) | 2001-05-24 |
| US20010001290A1 (en) | 2001-05-17 |
| EP0846160A1 (en) | 1998-06-10 |
| JPH11511324A (ja) | 1999-10-05 |
| ATE289348T1 (de) | 2005-03-15 |
| EP0846160A4 (en) | 2002-01-02 |
| US5840565A (en) | 1998-11-24 |
| CN1161469C (zh) | 2004-08-11 |
| EP0846174A4 (en) | 2003-02-05 |
| EP0846174A1 (en) | 1998-06-10 |
| US7132271B2 (en) | 2006-11-07 |
| WO1997008292A1 (en) | 1997-03-06 |
| CA2229405A1 (en) | 1997-03-06 |
| DE69634360T2 (de) | 2005-12-29 |
| US6159712A (en) | 2000-12-12 |
| JPH11514344A (ja) | 1999-12-07 |
| DE69634360D1 (de) | 2005-03-24 |
| US6673591B2 (en) | 2004-01-06 |
| CA2229163C (en) | 2011-04-05 |
| CA2229405C (en) | 2004-03-02 |
| WO1997008324A1 (en) | 1997-03-06 |
| MX9801423A (es) | 1998-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU707130B2 (en) | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression | |
| Kittel et al. | Rescue of influenza virus expressing GFP from the NS1 reading frame | |
| Komatsu et al. | Interferon-γ induced type I nitric oxide synthase activity inhibits viral replication in neurons | |
| Toth et al. | RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR | |
| JPH04504843A (ja) | 感染および過剰増殖障害の為の組換え療法 | |
| CN109276580A (zh) | 一种用于治疗肿瘤的病毒 | |
| CA3187433A1 (en) | Cell line for production of marek's disease virus vaccine and methods of making and using the same | |
| Stewart et al. | PKR's protective role in viral myocarditis | |
| Komatsu et al. | Mechanisms of cytokine-mediated inhibition of viral replication | |
| CN103232976A (zh) | 用于病毒生产的培养基补充物 | |
| Basler et al. | Immunity by Filoviruses | |
| US6864061B2 (en) | Method for screening compounds for anti-inflammatory activity | |
| WO2013138670A1 (en) | Yellow fever virus ns5 mutants as flavivirus vaccine candidates | |
| Závada et al. | Complementation and phenotypic stabilization of vesicular stomatitis virus temperature-sensitive and thermolabile mutants by avian myeloblastosis virus | |
| MXPA98001423A (en) | Methods to improve the production of viral vaccines in cellular cultivation through interruption suppression | |
| Schmidt et al. | Progression of a vesicular stomatitis virus infection in primary lymphocytes is restricted at multiple levels during B cell activation | |
| KR101293363B1 (ko) | 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물 | |
| Rodrigues | Interferon, virus vaccines and antiviral drugs | |
| Teague | LUBAC is required for the RIG-I mediated antiviral response | |
| Held | ISG15 in proteasomal degradation and MHC class I restricted antigen processing and development of a high-throughput assay for antigen presentation | |
| Walton | Activation and Subversion of MDA5-Dependent Immune Responses by the Engineered Oncolytic Poliovirus PVSRIPO | |
| Devoldere et al. | To refer to or to cite this work, please use the citation to the published version | |
| Kim | The role of the non-structural protein of human influenza A viruses (NS1A protein) during infection of human cells | |
| Smoak | The cardiac interferon response to reovirus infection | |
| Min | The role of the influenza NS1A protein during influenza A virus infection: evasion of the host anti-viral response |